Novel Drug Eases Charcot-Marie-Tooth Disability in Phase 3 Trial Novel Drug Eases Charcot-Marie-Tooth Disability in Phase 3 Trial

A novel, fixed-dose, three-drug combination therapy has provided"first evidence of meaningful improvement" in patients with Charcot-Marie-Tooth Type 1A disease in a new phase 3 trial.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news